SSStephen M. Sykes

Stephen M. Sykes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stephen M. Sykes has a total of 202 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Unfolded protein response signaling promotes myeloid cell production and cooperates with oncogenic mutation

    by Hyunjoo Choi, Sang-Eun Jung, Yesenia Earth, Hyojung Paik, Shuyang Lin, Jiye Yi, Maggie J. Cox, Stephen M. Sykes, Stephen T. Oh, Yoon-A Kang

    The unfolded protein response (UPR) promotes protein homeostasis under endoplasmic reticulum stress. UPR signaling has numerous functions in metabolism, cancer, immunology, and neurodegenerative diseases. Recent studies have also shown that UPR signaling plays an important role in hematopoietic stem and progenitor cell biology. However, whether UPR signaling regulates hematopoietic lineage fate decisions remains elusive. In this study, we found that FcγR− multipotent progenitor-3 (MPP3) generates erythroid lineage cells and that the Jak2V617F mutation leads to overproduction of erythroid cells by expanding FcγR− MPP3. We showed that UPR signaling increases myeloid cell production by promoting the transition of FcγR− MPP3 to granulocyte/macrophage progenitor (GMP)- producing FcγR+ MPP3 at the expense of the erythroid lineage via the X-box binding protein 1 (XBP1) pathway. Under disease conditions, UPR signaling cooperates with the Jak2V617F mutation and exacerbates the disease phenotype in a mouse model of polycythemia vera (PV) through the Activating transcription factor 4 (ATF4) pathway. Activation of UPR signaling also increased myeloid output in healthy donor bone marrow MPP cells, whereas skewing the output toward the erythroid lineage in bone marrow MPP cells from patients with PV. Together, our results identify a novel function of UPR signaling in hematopoietic lineage specification and provide critical insights into targeting UPR signaling in hematological malignancies.

  • Open Access

    Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms

    by Fan He, Shuyang Lin, Tim Kong, Daniel A.C. Fisher, Alexander B. Kim, Varun Ramesh, Molly Brakhane, Christopher T Letson, Matias Grodzielski, Maggie J Cox, et al.

    Dysregulation of galectins and global protein glycosylation have been reported in various cancers, but their role in myeloproliferative neoplasms (MPNs) have remained incompletely understood. We performed single-cell RNA sequencing (scRNA-seq) which revealed significant enrichment of galectin genes in MPN monocytes. Cell-cell communication analysis predicted monocytes as a pivotal mediator of cell interactions and galectin signaling as a robust input/output pathway for monocytes. We identified elevated expression of galectin-1 (Gal-1, LGALS1) in monocytes from both human MPN samples and mouse models. Mass cytometry (CyTOF) profiling of MPN blood samples demonstrated that recombinant galectin-1 (rGal-1) significantly increased levels of multiple inflammatory cytokines in monocytes without affecting other cell types. Incubation of CD14+ monocytes from MPN patients with rGal-1 led to markedly increased transcription and secretion of inflammatory cytokines. Mechanistically, we uncovered crosstalk between the TLR4 and Gal-1 signaling pathways, as evidenced by protein 3D modeling and co-immunoprecipitation. Notably, TLR4 inhibition abrogated Gal-1 mediated proinflammatory effects in monocytes. We further identified NF-κB-dependent signaling as a key downstream effector of Gal-1, as reporter assays demonstrated rGal-1 mediated activation of NF-κB signaling in a TLR4-dependent manner. We corroborated these findings in vivo in a murine model driven by MPLW515L in which genetic abrogation of Lgals1 ameliorated key MPN disease features, including leukocytosis and splenomegaly. Additionally, Gal-1 inhibition suppressed carrageenan-induced thrombosis and inflammation in vivo. In summary, we identify Gal-1 enrichment in MPN monocytes as a driver of monocyte-mediated inflammation through TLR4 and NF-κB activation and uncover a novel therapeutic avenue for MPNs.


  • Open Access

    ATF4 coordinates amino acid and nucleotide synthesis with selective protein translation to ensure proper DNA replication timing in leukemia cells

    by Jacklyn M. Huhn, Liana Valin, Mary Basse, Judith Sokei, Nishanth Gabriel, Esteban Martinez, Joice S. Kanefsky, Stephanie Stransky, Adrienne Dorrance, Ramiro Garzon, et al.

    Proper timing of DNA replication relies on sufficient nucleotide pools and replication machinery. The upstream regulatory programs that support the biomass production needed for DNA replication, particularly in the accelerated growth setting of cancer, remain incompletely defined. Here we show that the transcription factor ATF4 coordinates amino acid and nucleotide metabolism with selective protein synthesis to ensure proper DNA replication initiation and timing in acute leukemia. Specifically, ATF4 promotes the expression of enzymes that biosynthesize amino acids required for nucleotide production and drive the transcription of tRNA charging enzymes that sustain translation of a subset of proteins involved in replication origin firing. Consequently, ATF4 inhibition limits nucleotide biosynthesis and replication machinery, thereby disrupting DNA replication timing and leading to leukemia cell differentiation and death. Our findings indicate that ATF4 coordinates metabolic and translational programs to maintain DNA replication fidelity and the differentiation blockade in leukemia cells.


  • Open Access

    Targeting MTHFD2 disrupts mitochondrial redox homeostasis and restores venetoclax sensitivity in acute myeloid leukemia

    by Judith O. Sokei, Orsola di Martino, Mary Basse, Nishanth Gabriel, Liana Valin, Conner R. York, Nancy B.J. Arthur, Wujuan Zhang, Aaron R. Goldman, Francesca Ferraro, et al.

    One-carbon metabolism is frequently dysregulated in human cancer including acute myeloid leukemia. However, the mitochondrial mechanisms by which one-carbon enzymes support leukemia survival and therapeutic response remain incompletely defined. Here, we report that the one-carbon metabolism enzyme MTHFD2 is a critical regulator of acute myeloid leukemia nucleotide metabolism, redox homeostasis, and disease progression. We show that genetic ablation of MTHFD2 suppresses acute myeloid leukemia cell proliferation in vitro and significantly delays leukemia onset in a genetically engineered mouse model, while sparing healthy hematopoietic stem and progenitor cell function. Stable isotope tracing demonstrates that MTHFD2 supports de novo purine synthesis and sustains mitochondrial NADH and NADPH production. Consistent with this role, MTHFD2 inhibition increases mitochondrial superoxide levels, and combined purine supplementation and mitochondrial reactive oxygen species neutralization rescues acute myeloid leukemia cell viability. We also demonstrate that the small-molecule inhibitor DS18561882 directly inhibits mitochondrial MTHFD2 activity and phenocopies genetic deletion. DS18561882 exhibits activity across a cohort of 60 primary AML patient samples, synergizes with venetoclax in treatment-naïve acute myeloid leukemia, and restores venetoclax sensitivity in resistant AML models. These findings establish mitochondrial MTHFD2 as a genetically validated, therapeutically targetable metabolic vulnerability in acute myeloid leukemia and support targeting mitochondrial one-carbon metabolism to enhance and restore venetoclax response.

  • Open Access

    Dominant negative ATP5F1A variants disrupt oxidative phosphorylation causing neurological disorders

    by Sara M Fielder, Marisa W Friederich, Daniella H Hock, Jessie R Zhang, Liana M Valin, Jill A Rosenfeld, Kevin T A Booth, Natasha J Brown, Rocio Rius, Tanavi Sharma, et al.

    ATP5F1A encodes the α-subunit of complex V of the respiratory chain, which is responsible for mitochondrial ATP synthesis. We describe 6 probands with heterozygous de novo missense ATP5F1A variants that presented with developmental delay, intellectual disability, and movement disorders. All variants were located at the contact points between the α- and β-subunits. Functional studies in C. elegans revealed that the variants were damaging via a dominant negative genetic mechanism. Biochemical and proteomics studies of proband-derived cells showed a marked reduction in complex V abundance and activity. Mitochondrial physiology studies revealed increased oxygen consumption, yet decreased mitochondrial membrane potential and ATP levels indicative of uncoupled oxidative phosphorylation as a pathophysiologic mechanism. Our findings contrast with the previously reported ATP5F1A variant, p.Arg207His, indicating a different pathological mechanism. This study expands the phenotypic and genotypic spectrum of ATP5F1A -associated conditions and highlights how functional studies can provide an understanding of the genetic, molecular, and cellular mechanisms of ATP5F1A variants of uncertain significance. With 12 heterozygous individuals now reported, ATP5F1A is the most frequent nuclear genome cause of complex V deficiency.


  • Reprogramming of Fatty Acid Metabolism in Acute Leukemia

    by Judith Sokei, Joice Kanefsky, Stephen M. Sykes

    Fatty acids are essential biomolecules that support several cellular processes, such as membrane structures, energy storage and production, as well as signal transduction. Accordingly, changes in fatty acid metabolism can have a significant impact on cell behavior, such as growth, survival, proliferation, differentiation, and motility. Therefore, it is not surprising that many aspects of fatty acid metabolism are frequently dysregulated in human cancer, including in highly aggressive blood cancers such as acute leukemia. The aims of this review are to summarize the aspects of fatty acid metabolism that are specifically coopted in acute leukemia as well as current preclinical strategies for targeting fatty acid metabolism in these cancers.


  • Open Access

    Supplementary Figure S6 from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis

    by Nancy B.J. Arthur, Keegan A. Christensen, Kathleen Mannino, Marianna B. Ruzinova, Ashutosh Kumar, Agata Gruszczynska, Ryan B. Day, Petra Erdmann-Gilmore, Yiling Mi, Robert Sprung, et al.

    Supplementary Figure 6. (A-B) Bar graphs of the distribution of white blood cells (WBC) counts (1000/microliter), hemoglobin (Hb, grams/deciliter) and platelets (1000/microliter) in MycT58N/+ and Myc+/+mice at 8 and 12 weeks of age. None of the differences are statistically significant. (C) Bar graphs of the distribution of weight in 8-12 weeks old males (left panel) and females (right panel) MycT58N/+and Myc+/+showing no significant differences across genotype. (D-E) Bar graphs of the distribution of stem and progenitor cells in the bone marrow compartment of 6-8 weeks old MycT58N/+ and Myc+/+ as determined by flow cytometry analysis. None of the differences are statistically significant. (F) Confocal images of HSPCs isolated from healthy, 6 months old, MycT58N/+ and littermate controls mice. The blue is DAPI (nuclei), the red is LAMININ A/C (Alexa Fluor 647, nuclear envelope), and the green is MYC (Alexa Fluor 488). Scalebar 30 microns (µm). (G) MYC staining Mean Fluorescence Intensity (MFI) average in nuclear and cytoplasmic compartments of MycT58N/+and Myc+/+ mice showing increase cytoplasmic MYC signal in MycT58N/+ (two-tail t test, ***p<0.001). (H) Cytoplasmic to nuclear ratio of MFI MYC signal from (G) (two-tail t-test, **p<0.01). (I) Bar-graph of aggregation propensity of MYCT58N proteins compared to MYC wildtype (two-tail t-test, **p<0.01), as detected using PROTEOSTAT. (J-L) Number of stem cells and progenitor cells per femur of MycT58N/+and Myc+/+detected by flow cytometry in the bone marrow of moribund MycT58N/+mice at takedown. Age-matched littermate controls were taken down and analyzed side-by-side for comparison (*=p<0,05, all other comparison not significant). (M) Kaplan-Meier curve for MycT58N/+ secondary tumors transplant (n = 5 from 2 separate donors). (D-F) Flow cytometry analysis showing the distribution of hematopoietic progenitor cells.

  • Open Access

    Supplementary Data S8 from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis

    by Nancy B.J. Arthur, Keegan A. Christensen, Kathleen Mannino, Marianna B. Ruzinova, Ashutosh Kumar, Agata Gruszczynska, Ryan B. Day, Petra Erdmann-Gilmore, Yiling Mi, Robert Sprung, et al.

    Supplementary Data S8 Graph Based Cluster Biomarkers

  • Open Access

    Supplementary Figure S5 from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis

    by Nancy B.J. Arthur, Keegan A. Christensen, Kathleen Mannino, Marianna B. Ruzinova, Ashutosh Kumar, Agata Gruszczynska, Ryan B. Day, Petra Erdmann-Gilmore, Yiling Mi, Robert Sprung, et al.

    Supplementary Figure 5: (A-B) Confocal images of cytospins of patient-derived AML cells from bone marrow at diagnosis, with MYC mutations (A) and without MYC mutations (B). MYC (antibody 9,402) is in green, LAMININ A/C is red and DAPI is blue. Scalebar: 5 microns.

  • Open Access

    Data from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis

    by Nancy B.J. Arthur, Keegan A. Christensen, Kathleen Mannino, Marianna B. Ruzinova, Ashutosh Kumar, Agata Gruszczynska, Ryan B. Day, Petra Erdmann-Gilmore, Yiling Mi, Robert Sprung, et al.

    Purpose:Somatic missense mutations in the phosphodegron domain of the MYC gene (MYC Box I or MBI) are detected in the dominant clones of a subset of patients with acute myeloid leukemia (AML), but the mechanisms by which they contribute to AML are unknown.Experimental Design:To investigate the effects of MBI MYC mutations on hematopoietic cells, we employed a multi-omic approach to systematically compare the cellular and molecular consequences of expressing oncogenic doses of wild type, threonine-58 and proline-59 mutant MYC proteins in hematopoietic cells, and we developed a knockin mouse harboring the germline MBI mutation p.T58N in the Myc gene.Results:Both wild-type and MBI mutant MYC proteins promote self-renewal programs and expand highly selected subpopulations of progenitor cells in the bone marrow. Compared with their wild-type counterparts, mutant cells display decreased cell death and accelerated leukemogenesis in vivo, changes that are recapitulated in the transcriptomes of human AML-bearing MYC mutations. The mutant phenotypes feature decreased stability and translation of mRNAs encoding proapoptotic and immune-regulatory genes, increased translation of RNA binding proteins and nuclear export machinery, and distinct nucleocytoplasmic RNA profiles. MBI MYC mutant proteins also show a higher propensity to aggregate in perinuclear regions and cytoplasm. Like the overexpression model, heterozygous p.T58N knockin mice displayed similar changes in subcellular MYC localization, progenitor expansion, transcriptional signatures, and develop hematopoietic tumors.Conclusions:This study uncovers that MBI MYC mutations alter RNA nucleocytoplasmic transport mechanisms to contribute to the development of hematopoietic malignancies.